We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Blood Test Influences Clinical Decisions in Coronary Artery Disease

By LabMedica International staff writers
Posted on 22 Apr 2015
Clinicians need better approaches to evaluating women at midlife and beyond who present to primary care with chest pain and related symptoms such as an individual's current likelihood of having obstructive coronary artery disease. More...


A blood test that incorporates age, sex, and gene expression, influences medical decision-making in the evaluation of non-diabetic women presenting with non-acute typical or atypical symptoms, suggestive of obstructive coronary artery disease (CAD).

Scientists at the New York University School of Medicine (NY, USA) and their colleagues studied 320 women presenting to 16 primary care providers across nine practice sites and six states in the USA. The enrollees presented with stable symptoms suggestive of obstructive CAD and undergoing age/sex/gene expression score (ASGES) testing from the primary care providers in geographically diverse sites. The mean participant age was 57.8 years and the ASGES scores were pooled.

The investigators used the Corus CAD test (CardioDx; Redwood City, CA, USA). The Corus CAD test is the first and only commercially available blood test that can safely and conveniently help primary care clinicians and cardiologists assess whether or not a stable non-diabetic patient's symptoms may be due to obstructive coronary artery disease. The study indicated that women with low Corus CAD test scores of less than 15 were significantly less likely to be referred for further cardiac evaluation by their primary care clinicians within 45 days of follow-up.

The mean Corus CAD test score was 10.3 ± 8.2, with a range of 1, corresponding to a 1% likelihood of obstructive CAD to 38 corresponding to a 62% likelihood of obstructive CAD. Overall, 77.5% of women (248/320) had low Corus CAD test scores. The referral rate for further cardiac evaluation was 4% (10/248) among women with low Corus CAD test scores versus 83.3% (60/72) among women with elevated scores.

Joseph A. Ladapo, MD, PhD, the lead author of the study said, “Current testing approaches for identifying obstructive CAD have been shown to be less accurate in women than men, and these diagnostic challenges lead to both over-testing of low-risk women and under-testing of high-risk women. This study demonstrates that incorporating the age, sex, and gene expression score early in the diagnostic pathway, as a part of the patient's clinical assessment, can help clinicians rule-out obstructive CAD in menopausal women presenting with chest pain and other angina symptoms.” The study was published online on April 6, 2015, in the journal Menopause: The Journal of The North American Menopause Society.

Related Links:
New York University School of Medicine 
CardioDx 



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.